after the conference call??
Otrexup Insurance coverage? check!
Final package insert / Labeling? check!
Even medicare lined up? check!
Tier 3 status for managed care plans? check!
Launch end of January? check!
Insider sales - planned sales concern expressed by the analysts? Nope / Irrelevant!
QS-T ahead of schedule? check!
2015 NDA filing? check!
PFE / ATRS undisclosed (insert Advil 'Chen' Gel) on track? check!
Epi-pen, shipping product to TEVA, 2015 launch, AB rated product? check!
TEVA partnerships in tact? check!
File IND for QS-M mid 2014? check!
One new product per year for the next 5 to 10 yrs? check!
Naysayers still here? check!
Capitulation phase? check!
Sentiment: Strong Buy
2.500 targeted rhumatologists x ONLY 1 patient (each) switching to Otrexup x 7.000USD / year = 17.500.000 USD revenues. Not bad for such a very low objective. Add 1, 2, 5 or 10 patients and do the math!
Any FDA approved drug starting with an "A" means it has achieved therapeutic equivalence or bioequivalence to a particular referenced product - in this case mylan's branded epi-pen. On the flip side, starting out with a "B" means the FDA considers the drug product NOT to be therapeutically equivalent.
Here's what the FDA states: "Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence."
I added to my position today-check!. Willing to add more if the selling continues. I did this with CGEN a couple years back---bought a large bunch in the low 3's then added and added, its now 10. Check!
Right Jab, the pre launch prep work has been laid out down to the last detail which naturally gives a smallish sales staff a tremendous edge to, as I like to describe, hit the ground running. This part of the call confirmed exactly what I posted in The Risk Aversion Road to Success about 1 week ago. Even one of the analysts asked if the plan was to ease into the launch and make higher dollar commitments(personnel wise) as revenue ramps. High productivity to offset taking on added risk is Dr. Wotton's mantra so it wasn't a difficult post to think out.
On the point of 1 new product per year. The first MB contributor that I made the following comment was Loko of all people about 6 months ago. Basically what I posted was that once the company started generating FC Antares's growth picture jumps exponentially because management will deploy any excess capital into developing and commercializing additional in-house products or take on joint ventures in a 50/50 proposition. So the 1 product per year "CAN EASILY" evolve into 2-3 or more in a given year depending on the attractiveness of the opportunity and the free cash being generated at the time.
In Short, the only thing separating Antares RIGHT NOW from being an absolute juggernaut is the cash to pursue all the opportunities that I'm sure management is well aware of. We'll get there though, no question about it.
Cash is trash without a high ROI place to invest it!
Hi jab, another great post...I am going to be adding to my already 88k position in next several days ....will update once added and total count..hope my funds clear fast so that I can pick up in 3.70 range.
Great post; you have managed to put things in perspective. ATRS longs are obviously discouraged and unhappy about the PPS, but we have ourselves a great company here going on a Fire Sale!
I nearly doubled my position in ATRS in the last couple of days.
Sentiment: Strong Buy